INVO Bioscience, Inc. announced that at its Board of Directors meeting held on September 20, 2016, it was determined that it was in the best interests of the company to replace Dr. Claude Ranoux as President, Treasurer and Chief Scientist of the company. He will maintain his position as a Director. During the meeting on September 20, 2016, Kathleen Karloff was elected as Chairman of the Board, President and CEO of the company, and Robert Bowdring was elected as Treasurer and Secretary of the company, by a majority of the Board.

Dr. Ranoux was thereby replaced as President and Treasurer of the company, and was then removed as Chief Scientist. Kathleen Karloff and Robert Bowdring will maintain their positions as directors of the company. Kathleen Karloff was a Co-founder of INVO Bioscience and has over 30 years of experience in medical device and pharmaceutical manufacturing, clinical operations, regulatory affairs and quality systems. Prior to INVO Bioscience, Ms. Karloff was the Corporate Vice President of Operations for Psivida Ltd. Robert J Bowdring joined the INVO Bioscience Board of Directors in 2013 after serving as the company's Chief Financial Officer from 2008 until 2013.

He is currently Chief Financial Officer at Dynasil Corporation.